<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05027269</url>
  </required_header>
  <id_info>
    <org_study_id>AOC 1001-CS1</org_study_id>
    <nct_id>NCT05027269</nct_id>
  </id_info>
  <brief_title>Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients</brief_title>
  <acronym>MARINA</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple-Doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avidity Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avidity Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AOC 1001-CS1 is a randomized, double-blind, placebo-controlled, Phase 1/2 study to evaluate&#xD;
      the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple-doses&#xD;
      of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients&#xD;
      (MARINA).&#xD;
&#xD;
      Part A is a single dose design with 1 cohort (dose level). In Part A, the patient duration is&#xD;
      6 months as the treatment period is 1 day followed by a 6 month follow-up period.&#xD;
&#xD;
      Part B is a multiple-ascending dose design with 3 cohorts (dose levels). In Part B, the&#xD;
      patient duration is 6 months as the treatment period is 3 months followed by a 3 month&#xD;
      follow-up period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Through study completion, up to Day 183</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetic (PK) parameters</measure>
    <time_frame>Through study completion, up to Day 183</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetic (PK) parameters</measure>
    <time_frame>Through study completion, up to Day 183</time_frame>
    <description>Time to maximum plasma concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetic (PK) parameters</measure>
    <time_frame>Through study completion, up to Day 183</time_frame>
    <description>Terminal Half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetic (PK) parameters</measure>
    <time_frame>Through study completion, up to Day 183</time_frame>
    <description>Area Under the Concentration-time Curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetic (PK) parameters</measure>
    <time_frame>Through study completion, up to Day 183</time_frame>
    <description>fraction excreted (fe) in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AOC 1001 levels in muscle tissue</measure>
    <time_frame>Through study completion, up to Day 183</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and percentage change from baseline in DMPK mRNA knockdown</measure>
    <time_frame>Through study completion, up to Day 183</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and percentage change from baseline in Spliceopathy</measure>
    <time_frame>Through study completion, up to Day 183</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>DM1</condition>
  <condition>Myotonic Dystrophy 1</condition>
  <condition>Myotonic Dystrophy</condition>
  <condition>Myotonic Dystrophy Type 1 (DM1)</condition>
  <condition>Dystrophy Myotonic</condition>
  <condition>Myotonic Disorders</condition>
  <condition>Steinert Disease</condition>
  <condition>Myotonic Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Part A Single Dose: AOC 1001 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AOC 1001 will be administered once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Single Dose: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline will be administered once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Multiple Ascending Dose: AOC 1001 Dose Levels 2-4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AOC 1001 will be administered three times.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Multiple Ascending Dose: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline will be administered three times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AOC 1001</intervention_name>
    <description>AOC 1001 will be administered by intravenous (IV) infusion.</description>
    <arm_group_label>Part A Single Dose: AOC 1001 Dose Level 1</arm_group_label>
    <arm_group_label>Part B Multiple Ascending Dose: AOC 1001 Dose Levels 2-4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered by intravenous (IV) infusion.</description>
    <arm_group_label>Part A Single Dose: Placebo</arm_group_label>
    <arm_group_label>Part B Multiple Ascending Dose: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Genetic diagnosis of DM1 (CTG repeat length â‰¥ 100)&#xD;
&#xD;
          -  Clinician assessed signs of DM1&#xD;
&#xD;
          -  Ability to walk independently (orthoses and ankle braces allowed) for at least 10&#xD;
             meters at screening&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes that is not adequately controlled&#xD;
&#xD;
          -  BMI &gt; 35 kg/m2&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Congenital DM1&#xD;
&#xD;
          -  History of tibialis anterior (TA) biopsy within 3 months of Day 1 or planning to&#xD;
             undergo TA biopsies during study period&#xD;
&#xD;
          -  Recently treated with an investigational drug&#xD;
&#xD;
          -  Treatment with anti-myotonic medication within 14 days of Day 1&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Tai, MD</last_name>
    <role>Study Director</role>
    <affiliation>Avidity Biosciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Avidity Biosciences, Inc.</last_name>
    <phone>858-771-7038</phone>
    <email>medinfo@aviditybio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.aviditybiosciences.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DM1</keyword>
  <keyword>Myotonic Dystrophy 1</keyword>
  <keyword>Myotonic Dystrophy Type 1 (DM1)</keyword>
  <keyword>Myotonic Dystrophy</keyword>
  <keyword>DM</keyword>
  <keyword>Dystrophy Myotonic</keyword>
  <keyword>Myotonic Disorders</keyword>
  <keyword>Steinert Disease</keyword>
  <keyword>MARINA</keyword>
  <keyword>Avidity Biosciences</keyword>
  <keyword>Avidity</keyword>
  <keyword>AOC 1001</keyword>
  <keyword>Myotonic Muscular Dystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Myotonic Dystrophy</mesh_term>
    <mesh_term>Myotonic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

